跳至主要内容
临床试验/NCT00290056
NCT00290056Unknown4 期

Effect of Supplemental Intake of Omega-3 Polyunsaturated Fatty Acids on the Rate and Complexity of Spontaneously Occurring Ventricular and Supraventricular Arrhythmias in Patients With Implantable Cardioverter Defibrillator (ICD) - A Randomized Clinical Trial

Sheba Medical Center4 个研究点 分布在 1 个国家目标入组 105 人开始时间: 2005年11月最近更新:
适应症
相关药物

试验速览

阶段
4 期
入组人数
105
试验地点
4
主要终点
number of VT/VF episodes

研究概览

简要总结

We hypothesize that oral supplementation with omega-3 PUFA will decrease occurrence of arrhythmic events among post-MI, ICD recipients.

详细描述

This is a randomized, placebo-controlled, crossover, double- blind interventional study. Patients will receive 3.6 g of EPA and DHA fish oil and placebo oil for 6 months, randomly, in a crossover design, with a four month washout period between treatments.

Randomization will be stratified by ejection fraction (≤ 35% or > 35%), and the type of the index arrhythmia (VT - spontaneous or inducible by electrophysiologic study (EPS), versus other - VF, SCD, Primary prevention - MADIT II).

Ischemia severity was chosen to be evaluated by Single Photon Emission Computed Tomography (SPECT) during stress (dipyridamol infusion).

Subcutaneous adipose-tissue biopsy, a biomarker considered the gold-standard for the objective assessment of long-term habitual dietary intake of fish and marine omega-3 PUFA (EPA and DHA) will be obtain.

Compliance will be monitored by counting returned capsules or bottles and by measuring the omega-3 PUFA composition in red blood cells (RBC).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Double (Participant, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • post-MI patients.
  • Both single and Dual chamber ICD recipient.
  • implanted more than 3 months ago.
  • Agree to give written informed consent.

排除标准

  • Less than 18 years of age.
  • ICD implantation as a 'bridge' to heart transplantation.
  • Stable antiarrhythmic medication over the last month prior to enrollment.
  • Patients taking class I antiarrhythmic medication.
  • A projected lifespan less than one year.
  • Participation in another trial (during or within 90 days before the study).
  • Use of supplemental n-3 fatty acids during the last 3 months.
  • Women who are pregnant and of childbearing potential who do not use adequate contraception.
  • Patients known to have a history of recent drug or alcohol abuse. 10) History or current intestinal or hepatic disease.

结局指标

主要结局

number of VT/VF episodes

时间窗: continous

次要结局

  • All-cause mortality, cardiac mortality, recurrent and myocardial infarction.(continous)
  • Atrial arrhythmia and non-sustained ventricular arrhythmia (non-sustained VT or ventricular premature complex (PVC)) as documented by ICD memory or 24 hour ECG (Holter) recording.(24 hours)
  • Whether omega-3 PUFA supplementation exerts different effects according to ischemia severity assessed by stress perfusion nuclear imaging.(time of the test)

研究者

申办方类型
Other Gov

研究点 (4)

Loading locations...

相似试验

Effect of Supplemental Intake of Omega-3... | 临床试验